home / stock / xers / xers quote
Last: | $1.75 |
---|---|
Change Percent: | 1.14% |
Open: | $1.73 |
Close: | $1.75 |
High: | $1.78 |
Low: | $1.71 |
Volume: | 932,969 |
Last Trade Date Time: | 04/29/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.75 | $1.73 | $1.75 | $1.78 | $1.71 | 932,969 | 04-29-2024 |
$1.75 | $1.71 | $1.75 | $1.75 | $1.69 | 870,181 | 04-26-2024 |
$1.7 | $1.76 | $1.7 | $1.76 | $1.7 | 894,039 | 04-25-2024 |
$1.76 | $1.78 | $1.76 | $1.8 | $1.74 | 712,941 | 04-24-2024 |
$1.78 | $1.8 | $1.78 | $1.9 | $1.775 | 1,345,122 | 04-23-2024 |
$1.78 | $1.72 | $1.78 | $1.84 | $1.69 | 1,319,079 | 04-22-2024 |
$1.74 | $1.76 | $1.74 | $1.78 | $1.69 | 2,009,841 | 04-19-2024 |
$1.76 | $1.8 | $1.76 | $1.8 | $1.73 | 1,086,061 | 04-18-2024 |
$1.78 | $1.8 | $1.78 | $1.83 | $1.75 | 1,521,288 | 04-17-2024 |
$1.8 | $1.85 | $1.8 | $1.86 | $1.77 | 1,836,672 | 04-16-2024 |
$1.85 | $1.9 | $1.85 | $1.96 | $1.83 | 1,773,740 | 04-15-2024 |
$1.91 | $2.02 | $1.91 | $2.045 | $1.87 | 2,080,071 | 04-12-2024 |
$2.03 | $1.97 | $2.03 | $2.04 | $1.96 | 1,506,520 | 04-11-2024 |
$1.98 | $1.99 | $1.98 | $2.01 | $1.93 | 1,603,386 | 04-10-2024 |
$2.02 | $2.01 | $2.02 | $2.065 | $2.01 | 862,299 | 04-09-2024 |
$2.02 | $2.05 | $2.02 | $2.06 | $1.99 | 917,188 | 04-08-2024 |
$2.04 | $2.04 | $2.04 | $2.0788 | $2.0114 | 1,046,861 | 04-05-2024 |
$2.05 | $2.11 | $2.05 | $2.11 | $2.02 | 1,603,322 | 04-04-2024 |
$2.08 | $2.06 | $2.08 | $2.11 | $2.05 | 1,237,760 | 04-03-2024 |
$2.09 | $2.11 | $2.09 | $2.125 | $2.0625 | 943,725 | 04-02-2024 |
News, Short Squeeze, Breakout and More Instantly...
Xeris Pharmaceuticals Inc. Company Name:
XERS Stock Symbol:
NASDAQ Market:
Xeris Pharmaceuticals Inc. Website:
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris’ Chairman and CEO, will pres...
Achieved Total Revenue of over $44M in the fourth quarter – a 34% increase from same period prior year and generated approximately $164M for the full year 2023, a 49% increase versus prior year Ended 2023 with over $72M in cash, cash equivalents, and short-term investments achievin...